Boehringer Ingelheim

December 21, 2017

Boehringer Ingelheim, Roche Partnering on New Class of Bowel Disease Therapies

News

Boehringer Ingelheim and Roche are teaming up to develop a new class of inflammatory bowel diseases treatments. The partners will be focusing on therapies based on an innovative approach called Locked Nucleic ... Read more

November 16, 2017November 16, 2017

EU Approves Humira Biosimilar Cyltezo for Treatment of Chronic Inflammatory Diseases

News

The European Commission recently approved Cyltezo, a biosimilar to Humira (adalimumab), for the treatment of chronic inflammatory diseases in adults and children including inflammatory bowel diseases (IBDs) such as Crohn’s disease ... Read more

August 30, 2017August 30, 2017

FDA Approves Humira Biosimilar Cyltezo for Ulcerative Colitis, Crohn’s Disease, Other Illnesses

News

The U.S. Food and Drug Administration (FDA) has approved Boehringer Ingelheim‘s Cyltezo— a biosimilar of Abbvie’s Humira (adalimumab) — to treat Crohn’s disease, ulcerative colitis and a host of other diseases ranging from ... Read more

December 5, 2016

FDA Grants Orphan Drug Status to AbbVie’s Therapy for Pediatric Crohn’s Disease

News

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to AbbVie’s investigational drug risankizumab for the treatment of pediatric patients with Crohn’s disease. Risankizumab (ABBV-066) selectively blocks ... Read more

June 7, 2016June 7, 2016

Some Crohn’s Disease Patients Reach Remission with Risankizumab

Crohn's Disease, IBD News, News

Phase 2 clinical trial results showed that patients with moderate to severe active Crohn’s disease can achieve disease remission when treated with risankizumab, a Boehringer Ingelheim investigational biologic product. The study, “IL-23 ... Read more

May 26, 2016May 26, 2016

AbbVie Showcases IBD Therapies at Digestive Disease Week Annual Meeting

Crohn's Disease, IBD News, News, Ulcerative colitis

North Chicago, Illinois based multinational biopharmaceutical company AbbVie presented 13 abstracts at the Digestive Disease Week (DDW) Annual Meeting held May 21-24, 2016, at San Diego, California. Abstracts presented addressed ... Read more

November 11, 2015November 11, 2015

IBD Research to Advance with Boehringer Ingelheim New Partnerships

News

Boehringer Ingelheim recently announced a new collaboration with four leading U.S. scientific institutions to advance research and development of new therapeutic strategies for patients living with inflammatory bowel disease (IBD), ... Read more